New data supporting targeting Trk receptors with ACD856 for the treatment of Alzheimer's disease presented at AAIC 2021
Stockholm, Sweden, July 29, 2021. AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company's presentation and poster regarding the clinical candidate drug ACD856 for Alzheimer's disease, presented at the Alzheimer's Association International Conference (AAIC) 2021 on July 26-30 in Denver, USA, are now available on the company's website.The abstract, titled ACD856 – a novel positive allosteric